This report provides the most up-to-date information on key pipeline products in the global Nonalcoholic Fatty Liver Disease market. It covers emerging therapies for Nonalcoholic Fatty Liver Disease in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
The report provides Nonalcoholic Fatty Liver Disease pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
The report provides Nonalcoholic Fatty Liver Disease pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
Company:
The report provides Nonalcoholic Fatty Liver Disease pipeline products by the company.
Short-term Launch Highlights:
Find out which Nonalcoholic Fatty Liver Disease pipeline products will be launched in the US and Ex-US till 2025.
Today, RaySearch Laboratories AB (publ) publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.
This information is information that RaySearch Larboratiories AB...
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM.
The company aims to webcast the...
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website.
"Implantica had a very...
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...
Amwins Global Risks is delighted to announce Classic Cars and Cotswolds, an auction to raise money for the Matthew Wilson Multiple Myeloma Fund at Blood Cancer UK.
The online auction opens today and features Ferraris, Aston Martins, a Rolls Royce, a...
Regulatory News:
Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...